Quarterly report pursuant to Section 13 or 15(d)

Stock-based Compensation (Details Narrative)

v3.19.2
Stock-based Compensation (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Jun. 20, 2019
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2019
Jun. 30, 2018
Number of option purchase during period for vested       9,000  
Number of options outstanding   1,293,630   1,293,630  
Stock-based compensation expense   $ 66,476   $ 125,035  
Stock option expenses      
Employees [Member]          
Stock option contractual term 5 years        
Stock option exercise price $ 2.40        
Employees [Member] | Tranche One [Member] | In-license a new or additional drug [Member]          
Number of stock option granted 456,000        
Employees [Member] | Tranche Two [Member]          
Number of stock option granted 90,646        
Employees [Member] | Tranche Two [Member] | Phase 2a trial for PCS-499 Complete [Member]          
Number of stock option granted 90,646        
Employees [Member] | Tranche Two [Member] | Up-List From The OCTQB [Member]          
Number of stock option granted 271,938